Lupin acquires Portfolio of products worth Rs325cr of Anglo-French Drugs -; Industries

18 Jan 2022 , 01:56 PM

Lupin Ltd.’s share gained over 1% after its announcement to acquire a portfolio of Brands of Anglo-French Drugs & Industries & associates, to strengthen its portfolio in vitamins, supplements, and minerals. 

The portfolio of products that is being acquired falls within the business line of the company and will enable the addition of established brands with high recall amongst healthcare professionals, especially in the Minerals, Vitamins, and supplements category.

This will create new value for the company and would lead to EBITDA margin accretion, the company said in the filing.

The acquisition will be completed by March 2022. Company is paying a consideration of about Rs 325 crores including working capital amounting to Rs 9 crores, partly on cash and debt basis.

To be precise, the acquisition is only of a portfolio of products and not any unit or division of the company.

Lupin Ltd is currently trading at Rs952.85 up by Rs10.3 or 1.09% from its previous closing of Rs942.55 on the BSE. The scrip opened at Rs942 and has touched a high and low of Rs961.50 and Rs936.80 respectively.